AIMD vs. FBRX, GDTC, VINC, IBIO, BFRG, LUMO, CPIX, NRBO, APLM, and MEIP
Should you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Forte Biosciences (FBRX), CytoMed Therapeutics (GDTC), Vincerx Pharma (VINC), iBio (IBIO), Bullfrog AI (BFRG), Lumos Pharma (LUMO), Cumberland Pharmaceuticals (CPIX), NeuroBo Pharmaceuticals (NRBO), Apollomics (APLM), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical preparations" industry.
Forte Biosciences (NASDAQ:FBRX) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, community ranking, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.
Forte Biosciences has a net margin of 0.00% compared to Forte Biosciences' net margin of -15,348.14%. Forte Biosciences' return on equity of -55.38% beat Ainos' return on equity.
In the previous week, Forte Biosciences had 2 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Forte Biosciences and 0 mentions for Ainos. Ainos' average media sentiment score of 1.14 beat Forte Biosciences' score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the media.
Ainos has higher revenue and earnings than Forte Biosciences.
Forte Biosciences currently has a consensus target price of $3.38, suggesting a potential upside of 492.11%. Given Ainos' higher probable upside, research analysts clearly believe Forte Biosciences is more favorable than Ainos.
Forte Biosciences has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Ainos has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.
Forte Biosciences received 26 more outperform votes than Ainos when rated by MarketBeat users.
77.6% of Forte Biosciences shares are owned by institutional investors. 10.5% of Forte Biosciences shares are owned by company insiders. Comparatively, 4.6% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Forte Biosciences beats Ainos on 8 of the 13 factors compared between the two stocks.
Get Ainos News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
